Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” [Dig. Liver Dis. 48 (2016) 360–370]

In the last paragraph of Section 1, the sentence "VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]" should be replaced with: "VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]".

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2b7IN66
via IFTTT